Here, we use a closed-loop discovery and optimization approach for searching the peptide sequence space. Combining an evolutionary algorithm with machine learning and in vitro assay allowed for rapid development of new antimicrobial peptides.
INTRODUCTION
Natural biological polymers, such as peptides and RNAs, play a crucial role to maintain cellular functions. It is widely known that short RNA molecules interfere with gene expression within eukaryotic cells. 1 RNA molecules with enzymatic functions (ribozymes) are involved in various intracellular processes, such as RNA selfsplicing. 2 Peptides are known to function as signaling molecules, such as hormones and neurotransmitters. 3 Antimicrobial peptides (AMPs) are yet another example of such natural functional biopolymers. 4 They are essential to the immune systems of all multicellular organisms as they have evolved to cope with bacterial invasion and infection. AMPs have been investigated as new antibiotic agents, 5 and more than 2,600 peptides that display antimicrobial activity from a broad range of organisms, including bacteria and mammalian cells, have been isolated. 6 Although the main mode of action causing bacterial death is disruption of the integrity of the bacterial membrane, AMPs have a wide variety of effective antimicrobial mechanisms, including the inhibition of DNA, RNA, and protein synthesis, to increase their efficacy to combat invading pathogens. 7, 8 Methodologies to artificially discover such functional biopolymer sequences have been challenging because of the massive size of possible sequence space. 9 Conventionally, in vitro evolutionary methods, such as mRNA display and liposome display, 10, 11 are used to tackle this combinatorial problem by generating billions of variants and screening them in a high-throughput fashion. However, there are limitations in these methodologies, 12 The Bigger Picture Biological evolution is a powerful way to produce new form and function but requires a fully functional biological organism. Here, we developed a closedloop artificial evolution system and applied it to the exploration of antimicrobial peptides (AMPs). AMPs are a promising class of antibiotics to combat this issue because of their diverse mechanisms of action. However, discovery of antimicrobial peptides has been difficult because of a massive number of possible peptide sequences. Using this approach, we identified AMPs with improved potency. This method employs a genetic algorithm with peptide sequence as the "gene" and in vitro bacterial assay as "fitness." In addition, efficient predictions by machine learning further accelerated the process, showing up to a 160-fold potency increase within only three optimization rounds. This demonstrates a possibility of optimizing peptides without relying on an existing physicochemical database. such as complex target-specific assay methods that are generally not transferrable to different experiments.
As an alternative method, rational design has long been studied to obtain molecules with a designed property. For example, in the case of AMPs, analogs of known natural AMPs were designed by modifying their physicochemical properties in order to improve antimicrobial activity and decrease toxicity to human cells. 8, 13, 14 This approach has identified peptides with improved antimicrobial activity. However, it has also illustrated the difficulty of rational AMP design because the physicochemical properties of peptides do not always correlate with antimicrobial activity. Indeed, de novo designs have been studied by defining sequence patterns of known AMPs to predict potent peptide sequences, which has revealed that specific motifs in a sequence are crucial for potent antimicrobial activity. 15, 16 To overcome the difficulty in improving knowledge-based AMP designs, machine-learning-based approaches, such as artificial neural network models combined with chemoinformatic methods, were used to capture more complex motifs of antimicrobial activities. 7, 17, 18 Indeed, such approaches have proved important applied to drug design. 19 Although these designs have demonstrated promising predictive power, they require relatively large datasets for accurate predictions as well as careful parameter adjustments depending on the starting peptide library.
In contrast, genetic algorithms 20 with experimentally characterized feedback have allowed optimization of molecules with desired biological or chemical activities from small starting libraries. 21, 22 This method has been applied to optimize relatively short peptides, 23, 24 but optimizing longer peptides by using genetic algorithms can be challenging. This is because the number of possible amino acid combinations is huge (e.g., 20 13 z 8 3 10 16 combinations for 13-mer peptides) and a search within the combinatorial space would require a large amount of experimental validation. This would limit optimization of AMPs considering that the synthesis of peptides is still costly. In this study, we propose a general methodology for evolution of physical objects (Scheme 1), including functional biomolecules. The method starts with a (population of) target object(s), which are physically synthesized. They are then ranked according to the results of the assay that is used for evaluating the effectiveness of the AMPs, whereby the best ones are used to produce a new population for the next generation.
To demonstrate its capability, we applied this method to discover effective AMPs by starting from a natural AMP. Although we used a similar methodology to evolve the physico-chemical properties of oil-in-water droplets successfully, 25 the application to AMP evolution is not straightforward because it could be hampered by other factors, such as the high cost of peptide synthesis. To circumvent this issue, here we combined the evolutionary method with machine learning, which provides more efficient predictions when generating the next generation.
Our method differs from previously proposed in silico optimization algorithms that couple evolutionary algorithms and machine learning to discover AMPs as follows. Firstly, we used the interactive process of in silico prediction by a machine-learning model and experimental assay to screen better AMP candidates. This was initiated by the selection of a target sequence, the generation of a population, and physical synthesis of each of the members of the population for testing. In contrast, the previously proposed algorithms performed virtual screening of potential candidates by using existing knowledge or an existing database (e.g., structure-activity relationship) of AMPs during evolutionary optimization. 18 Because of this all-in-silico optimization process, such algorithms are inevitably database dependent. On the other hand, our method is capable of optimizing a desirable feature of target compounds (in this case peptides) even if no preceding information or databases are available. This is because the evolutionary algorithm constructs its own database as it performs an online in vitro assay through the iterative process. For this reason, our algorithm can be a general methodology that applies to any functional polymers-not just AMPs-and can perform optimization by bootstrapping the assay to the synthesis process. Furthermore, as a control experiment, we compared the evolutionary algorithm-based optimizations guided by predictions from a machine-learning model and by random mutations. This is because we hypothesized that predictions by machine learning would allow us to navigate such massive peptide sequence space efficiently without synthesizing a large number of peptides and thus accelerate the evolutionarily driven search through such a large space. In theory, this would enable the discovery of potent AMPs in a more efficient manner and thus reduce the amount of chemical synthesis required, which is generally the most expensive and most timeconsuming part of the optimization process.
As a proof-of-concept study, we started from a natural AMP to show that the algorithm can successfully identify peptide sequences with improved antimicrobial activity against Escherichia coli. The optimization of AMPs proceeded as follows (Scheme 2): In the pre-optimization process (left), two peptide libraries, generations A (G-A) and B (G-B) were identified in silico on the basis of a natural AMP, which we refer to as the wild-type (WT) sequence hereafter. The peptides were synthesized by Scheme 1. General Schematic Describing the Evolutionary Process The circle represents the robotic process with the computational algorithm. In the first step, a random selection of the polymer sequence population is used as the starting polymer sequence population, and this forms the sequences experimentally synthesized in a peptide synthesis robot. The recorded polymer sequence activities then undergo analysis against a user-desired property (e.g., IC 50 ) in the evaluation step. The sequences are ranked in terms of the desired property automatically, and those of poorest quality are rejected in the ranking step, allowing a new population to be selected. Meanwhile, the accepted sequences are used as a basis for creating a new sequence population after random mutation and crossover. an automated solid-phase method and evaluated in vitro. We analyzed the results to determine the approximate fitness values (i.e., expected improvements in antimicrobial activity) of individual amino acid substitutions by using a generalized linear model. In the optimization process (right), we prepared a fitness matrix by using the calculated fitness values and used it to predict potential amino acid substitutions. The in silico library was synthesized and evaluated in vitro. The fitness matrix was then updated at each round of optimization.
RESULTS
The optimization process went as follows. At each round, a new library of peptides was generated on the basis of predictions from the generalized linear model and evaluated experimentally. The antimicrobial activity of peptides improved rapidly with this method within a relatively small number of experimental cyles. The optimization of antimicrobial peptides was conducted as illustrated in Scheme 1. A 13-mer peptide, Temporin-Ali (FFPIVGKLLSGLL-NH 2 ) was chosen as a starting WT peptide because of its known moderate antimicrobial activity. 26 The optimization comprises two sub-processes, a pre-optimization and an optimization process. In the pre-optimization process (Scheme 2, left column), a library of peptide sequences, called G-A, was created with the position-specific interactive basic local alignment search tool (PSI-BLAST), which iteratively searches for sequences in the protein databases as it would a sequence of interest (see Supplemental Experimental Procedures). 27 We used PSI-BLAST rather than BLAST because the former can find distantly related, functionally similar sequences. We selected 93 sequences from the search for assay with 96-well plates. The WT sequence was compared with sequences in the PSI-BLAST database, and sequences with high identity scores, such as the WT sequence, were selected. We ranked all amino acid substitutions in G-A by frequency and generated G-B by applying the 93 most frequent single-amino-acid substitutions to the WT sequence. We then synthesized G-A and G-B and evaluated their antimicrobial activities in vitro by measuring the half maximal inhibitory concentration (IC 50 ) against E. coli (MG1655 strain). We used the in vitro evaluation data to train a generalized linear model that performs a regression analysis on amino acid substitutions (see Supplemental Experimental Procedures) and changes in IC 50 . A coefficient for each substitution corresponds to the expected decrease in IC 50 value and is presented as a value in a fitness matrix.
In the optimization process (Scheme 2, right column), we generated a library of new 90 peptide sequences in silico by substituting amino acid residues of the most potent peptide in the previous generation. Substitutions were introduced with a probability proportional to values in the fitness matrix. Those peptides were then . Then, we updated the fitness matrix by performing regression on all the in vitro data. The optimization process was repeated for three generations until the IC 50 improvement saturated. In order to assess the effect of the fitness matrix, we performed a control optimization experiment for three generations by introducing random amino acid substitutions instead of predicting advantageous substitutions by using the matrix. The IC 50 values of peptides in the optimization experiment, along with that of the WT peptide (81.0 mM, dashed line), are shown as boxplots in Figure 1A . The average changes in IC 50 values in relation to the WT values are shown as bar plots in Figure 1B , and the WT and the most potent sequences in individual generations are in Table 1 . In G-A and G-B, most peptides were less potent than the WT peptide, whereby they demonstrated 9.3-and 6.7-fold higher average IC 50 values, respectively, than the IC 50 of the WT peptide. In the first generation (G1), only a few peptides presented improved antimicrobial activity, of which the lowest IC 50 value was 0.75 mM; most of the peptides in G1 showed weaker antimicrobial activity than the WT peptide.
In the second generation (G2), more peptides demonstrated improved antimicrobial activity, and the average IC 50 value decreased to 71.5 mM. The lowest IC 50 value also decreased to 0.5 mM. In the third generation (G3), although there was no improvement in the lowest IC 50 value, most peptides demonstrated very strong antimicrobial activity. The average IC 50 value significantly improved (12.4 mM), such that it was 6.5-fold lower than that of the WT peptide. The most potent peptide was found in G2, which had an IC 50 value (0.5 mM) 162-fold lower than that of the WT peptide. This peptide is referred to as the ''best peptide'' hereafter. Other peptides with strong antimicrobial activity were also identified (Table S1) ; 44 new peptides (29.1%) of 141 peptides tested showed IC 50 values lower than 4.1 mM (i.e., 20-fold decrease in IC 50 ) within three generations.
The fact that there were no improvements in terms of IC 50 in G3 suggests that the optimization of AMPs was converging within three generations. A possible explanation can be found in the fitness matrix ( Figure 1C ). After each generation, we re-calculated the fitness matrix to predict which amino acid substitution (at which locus) would be likely to improve the antimicrobial activity. When we predicted G3 substitutions by using the data from G-A, G-B, G1, and G2, the maximum of the fitness matrix values dropped sharply in comparison with the previous generation. The average value also decreased. Because the fitness matrix values can be interpreted as the "expectation" for each amino acid substitution to improve the activity, the data suggest that the model predicted a lower increase in the antimicrobial activity (i.e., converging). The reason for a smaller standard deviation can be simply attributed to the model prediction. As the model collects more experimental data as the optimization proceeds, predictions by the model and the data become more and more accurate. Thus, in the later generations, the model tended to select amino acid substitutions that were likely to improve as AMP or less likely to decrease the efficacy. With the implementation of the genetic algorithm, a peptide with the strongest activity in the previous generation was carried over to the next generation, and the core effective substitutions were maintained. On the other hand, we introduced new potentially good substitutions into the peptide to generate a set of peptides for the next generation. As a result, the efficacy data for the G3 peptides showed a smaller standard deviation than the previous one. To investigate the convergence of the optimization process further, we performed additional experiments. First, we identified 20 amino acid substitutions that were likely to increase the antimicrobial activity by screening the IC 50 data for all the sequences synthesized in the previous generations (see Table S3 ). We then generated a new set of 39 different sequences by introducing the selected substitutions randomly into the WT sequence. We refer to this peptide set as ''strong substitutions.'' As a result, we found that the IC 50 values of these peptides varied from 1.73 to 1,155.3 mM with an average IC 50 value of 40.8 mM (2-fold increase over that of the WT peptide). Because the new peptide set did not show any improvements over the best peptide in G2, this would support the notion that the optimization converged within the three rounds of optimization, as well as the analysis of the fitness matrix values ( Figure 1C ).
Peptides from the control experiment demonstrated relatively poor improvements in antimicrobial activity (Figure 1, red) . Although 44 peptides (17.2%) within the 256 peptides tested showed IC 50 values lower than 4.1 mM, up to a ca. 60-fold decrease, the others showed a diverse range of antimicrobial activity. In fact, the average IC 50 value of the third control generation was still 2.6-fold higher than that of the WT peptide. However, the IC 50 values of the most potent peptides in the control generations were comparable (1.3 mM; Table 1 ) with those in the The amino acid residues substituted from the WT sequence are underlined. Net charges and hydrophobic moments were calculated with the Peptides package in R. Hemolytic potency was predicted with HemoPI, 29 and lower values indicate that peptides are less hemolytic. non-control generations (0.5-2.0 mM). In addition, the optimized peptide sequences in both cases were relatively similar. This result indicates that the genetic algorithm used to optimize the WT peptide was indeed effective at identifying a peptide with high antimicrobial activity. However, because of the nonlinear effect of amino acid substitution, the entire population in the control generation showed diverse antimicrobial activity levels. This also illustrates that the fitness matrix indeed played an important role in the search for multiple potent AMPs and not just the best one.
We calculated the physicochemical properties of all the peptides evaluated to investigate the mechanism behind the improvement in antimicrobial activities. The following peptide properties were calculated: molecular weight (g/mol), net charge, hydrophobicity, hydrophobic moment, isoelectric point (pI), aliphatic index, instability index, and Boman index. Although moderate correlations between the calculated parameter values and IC 50 were observed in some of the properties (Figures S1-S3), the results indicated that finding explicit correlations between them is not a trivial task, especially because of the many outliers in the plots ( Figure S3 ). Among others, net charge and hydrophobic moment, the physicochemical properties known to be important for antimicrobial activity, showed relatively good correlation with IC 50 values. Average changes in net charge and hydrophobic moment in relation to those of the WT peptide are shown in bar plots in Figure 2 . The average net charge was increased through the optimization process ( Figure 2A ). As a result, the peptides in the later generations were positively charged, which indicates better binding to the negatively charged bacterial membrane than the WT peptide. 28 The hydrophobic moment for the peptide rotation angle of 100 also increased through the optimization process ( Figure 2B ). This suggests that the peptides in the latter generation may have formed amphipathic helical structures with hydrophilic and hydrophobic amino acid residues on each side of the helix, 29 which facilitated the attachment and insertion into bacterial membranes. 5 The increased hydrophobic moment indicated that the peptides in latter generations improved the spatial amphiphilicity if a peptide took a helical structure. Amphipathic a-helical peptides are known to be more potent than peptides with less-defined secondary structures. 5 In fact, the best peptide had a higher value for hydrophobic moment (0.74) than the WT sequence (Table 1 and Figure S3B ). To confirm this, we performed de novo structural reconstructions by using PEP-FOLD3, 30 and they indicated that the best peptide formed a longer helical structure than the WT peptide and other sequences in G1 and G2 ( Figures 3A and S4 ). These changes in secondary structure were confirmed by circular dichroism (CD) spectroscopy. The CD spectrum of the WT sequence and other sequences in G1 and G2 indicated a random coil structure, whereas that of the best peptide showed a profile typical of an a-helical structure ( Figures 3B and S4B) . These results strongly suggest that the best peptide with a high hydrophobic moment and helical structure allowed better disruption of the bacterial membrane. 28 However, care must be taken when considering these two measures (hydrophobic moment and helicity) in relation to the antimicrobial activity. Although the hydrophobic moment showed moderate correlation with the antimicrobial activity ( Figure S3B ), it does not mean that peptides with high hydrophobic moment always have helical structures. In fact, some of the peptides with a high hydrophobic moment ( Figure S4C ) were predicted to have less-defined structures despite the antimicrobial activity (IC 50 < 2.5 mM).
In terms of the peptide sequence, the helical wheels showed that there were more positively charged amino acid residues located on one side of the helix in the best peptide, the opposite of the hydrophobic sector, whereas the WT sequence had only one positively charged residue ( Figure 3C ). This change occurred not only for the best peptide but also for other peptides in G2 and G3 ( Figure S5 ). They had multiple positively charged residues at locations six, seven, and ten ( Figure S6 ). The result illustrates that the model-based predictions successfully identified favorable substitutions, 31 which significantly improves the antimicrobial activity.
As potent AMPs, it is important that the peptides selectively attack bacterial cells while keeping host cells intact. To confirm this, we examined potential hemolytic activity and cytotoxicity of the optimized peptides by using in silico predictive models, called HemoPI 6 and ToxinPred, 32 respectively (see Table 1 ). The predicted hemolytic potency was gradually improved over the generations. In fact, we experimentally confirmed the low hemolytic activity by using the best peptide and red blood cells, which showed only 1% lysis even at a higher concentration than the IC 50 ( Figure S9 ), and ToxinPred also predicted that all the peptides in Table 1 were non-toxic. We speculate that this improved peptide activity might be related to the fact that this optimization process showed evolutionary steps similar to the natural evolution of antimicrobial peptides ( Figure S10) . 33 Furthermore, we tested the efficacy of the best peptide against drug-resistant bacterial strains ( Figure S11) . To assess the efficacy in a comparable manner, we used drug-resistant E. coli MG1655 strains that we obtained by serially culturing the WT strain (the same strain used for the in vitro assay above) under single or multiple antibiotic stress. 34 Despite the fact that the bacterial strains are resistant to various types of antibiotics, including a peptide antibiotic polymyxin B or combinations of them, IC 50 values of the best peptide against the drug-resistant strains were still low (approximately 1.5-2.0 mM). Although the efficacy against clinically isolated drug-resistant bacteria may be different, this result suggests that the optimized peptide is also effective against drug-resistant bacteria that are difficult to treat with existing antibiotics.
DISCUSSION
In summary, we developed a new approach to the design of AMPs by combining an evolutionary algorithm, machine-learning-based prediction, and in vitro bacterial assays. This method rapidly improved antimicrobial activity, such that it achieved 162-fold more than the original peptide within three generations. The best peptide identified here has one of the lowest IC 50 values among the previously known AMPs, despite the short sequence length. 34 In addition to the best peptide, 44 new peptides were found to be highly potent with 20-fold lower IC 50 values than the WT peptide. This discovery of multiple potent peptides is remarkable considering the number of peptides tested through the pre-optimization and optimization processes (291 of 8 3 10 16 possible peptides). Because the other factors such as low cytotoxicity are also crucial for AMPs, identification of multiple potent AMPs by the model prediction would be useful for further screening of antimicrobial agents. In fact, all the peptides in G3 were predicted to be non-toxic partially because of the natural origin of the WT peptides (i.e., Temporin-Ali isolated from a frog). 26 Although we evaluated the synthesized peptides with the antimicrobial activity on E. coli in this study, the optimization method can adapt other measures-such as the IC 50 of multi-drug-resistant bacteria, hemolytic potency, and cytotoxicity-to calculate the fitness matrix. In addition, it is also possible to use multiple measures by performing multivariate regression with the generalized linear model.
One of the advantages of this optimization method is that it does not require any prior knowledge before starting the process. This is because of the iterative nature of the process that couples in silico algorithm with experimental validation. This makes a stark contrast with previous all-in-silico algorithms, where a database of optimized materials (e.g., AMPs) 35 is crucial. Our approach constructs its own database as the algorithm runs the optimization process. Experimental validation, however, generally comes with a high cost for chemical synthesis. This can be mitigated by machine-learning-based efficient prediction. Any peptide sequences can thus be used as a starting peptide for optimization by this method, although only one natural AMP was tested in this study. Most of the known natural AMPs have not yet been utilized in clinical or industrial processes because they have only moderate direct antimicrobial activity that works efficiently at the site of infection in harmony with other immune systems. [36] [37] [38] Our method can potentially identify a series of potent peptides by using those natural AMPs as starting peptides. Furthermore, we also anticipate that this method would be applicable to exploring the broader sequence space of peptides or other polymers. 39 For example, incorporation of new components such as non-canonical amino acids (ncAAs) would improve the chemical diversity of AMPs. 40, 41 Discovery and optimization of AMPs containing ncAAs with conventional in silico methods are currently challenging because they rely on existing databases of physicochemical properties or efficacy. However, our method proposed here does not require any prior information to perform evolutionary optimization and hence could open up a path for incorporating a wider range of molecular building blocks to discover novel AMPs as well as other functional polymers. In future work, we will aim to explore sequence space more broadly to see how algorithm-based evolutionary systems with a digital genome can be used to explore AMPs and other properties from entirely random sequences.
EXPERIMENTAL PROCEDURES
Because the details of the in silico optimization algorithm and the in vitro bacterial assay require a long and detailed technical description, please refer to the Supplemental Information. 
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Using Evolutionary Algorithms and Machine Learning to Explore Sequence Space for the Discovery of Antimicrobial Peptides Table S1 .
Relative frequencies of altered amino acid residues Figure S5 . Relative frequencies of amino acid residues at each locus in each generation. These figures were generated using WebLogo, 1 an online sequence logo generator. The net height of each stack indicates the sequence conservation at each position, calculated in bits. The height of a symbol within the stack correlates the relative frequency of the corresponding amino acid at a locus. Positively charged residues, hydrophobic residues and other residues are shown in red, blue and black, respectively. Figure S6 . The frequency of altered amino acid residues at each location in a 13-mer sequence. Generation A and B, one to three, and control generation one to three were shown in green, yellow, and red, respectively. The generation one and control generation one are shown in dotted lines, Generation A, two and control two are shown in dashed lines and Generation B, three, and control three are shown in solid lines, respectively. 10 pointed that the natural evolution of antimicrobial peptides found across bacterial to primates showed decreasing aggregation index and increasing R/K ratio as the evolution proceeds toward primates. The optimization process in the non-control generation generally shows a similar pattern, i.e. aggregation index decreased over time whereas R/K ratio increased. Figure S11 . In vitro assay of the best peptide against drug-resistant E. coli MG1655 strains, which was obtained by exposing a wild-type drug-susceptible MG1655 strain to various single or multiple antibiotic stress. (A) The dose response curve of the best peptide against single-drug resistant E. coli strains. They are resistant to ampicillin (AMP), tetracycline (TET), chloramphenicol (CHL), nitrofurantoin (NIT), kanamycin (KAN), rifampicin (RIF), and nalidixic acid (NAL), respectively. The IC50 was similar, around 1.5-2.0 μM for all of the strains (B) The dose response curve of the best peptide against multi-drug resistant E. coli strains. They are resistant to two antibiotics (e.g. nitrofurantoin and nalidixic acid, NIT-NAL). The IC50 values of the multi-drug resistant strains were similar to that of the WT susceptible strain. 
Frequency of amino acid residues
Example of MS and HPLC analysis
Potent peptides from optimization experiment
Supplemental Experimental Procedures
Strategies for optimizing peptide sequences
Pre-optimization process A 13-mer peptide, Temporin-Ali (FFPIVGKLLSGLL-NH2), was chosen as the WT sequence because of its broad-spectrum antimicrobial activity. The peptide was identified from skin secretions of a frog, Amolops loloensis. Based on the WT sequence, two generations of peptides, Generation A and B, were first created for pre-optimization process. Generation A contains peptide sequences from a public database. 93 candidates with as high identity scores as the WT sequence were selected using PSI-BLAST (NCBI) with the following parameters: BLOSUM62 was used for matrix, Gap costs were Existence:11 and Extension: 2, PSI-BLAST threshold was 0.002. A non-redundant protein sequence was used as a search database. The PSI-BLAST search was iterated three times. If a candidate contains one or more deletions, they were filled in with the WT residues to create 13-mer sequences. Generation B was created from Generation A. Individual amino acid substitutions present in Generation A were ranked by frequency. The most frequent 93 substitutions were introduced to the WT sequence to produce a new library of sequences. All the peptides in Generation A and B were synthesized and their IC50 values were measured against the MG1655 strain of Escherichia coli to generate a fitness matrix as described below.
Fitness matrix calculation
A fitness matrix can predict a possible antimicrobial activity increase of a peptide when an amino acid residue in a peptide is substituted with another residue. It was prepared from the measured IC50 values and used to generate a new set of peptides for a following optimization round. The matrix was first generated based on measured IC50 values of Generation A and B, and updated at the end of each optimization round. The matrix was calculated as follows: at first, a relative IC50 of peptide sequence ( 50 ) was calculated as ( 50 × )/( 50 × ) , where 50 and 50 were the measured IC50 of the wild-type sequence and peptide , respectively. and are the purity of synthesized wild-type peptide, and peptide . Then the relative IC50 value were fitted to a generalized linear model: where ( = 1, ⋯ ,13, = , , ⋯ , ) is the fitness coefficient, the increase of antimicrobial activities when the i-th amino acid residue is replaced by k. is a link function and a logarithmic function is used in the current case.
represents the presence or absence of amino acid substitution. For example, if the first amino acid in a peptide sequence is replaced by alanine (Ala), it was represented as 1 = 1 otherwise 0. is an error term for the sequence . A quasi-Poisson distribution was used as the probability distribution. Fitting was performed using R. After fitting was completed, the obtained coefficient values were used as fitness values in the fitness matrix.
Optimization process
At the beginning of each generation of the optimization process, 90 new peptides were generated in silico by introducing up to three random amino acid substitutions to the most potent peptide in the previous generation. For the first generation, the most potent peptide in Generation A and B (FFPIVGKLLSGLF-NH2) was used to generate the library. Probabilities of random amino acid substitutions were biased by the fitness matrix. Namely, substitutions that would improve antimicrobial effect were more likely to occur whereas the other substitutions were suppressed. Substitutions that never occurred previously had a flat probability. The new peptide sequences were synthesized by a parallel peptide synthesizer and IC50 values were measured by in vitro bacterial assay (see below). The fitness matrix was then updated by incorporating a new set of IC50 measurement data. Generation three had 30 new sequences which are repeated three times to assess the reproducibility.
Identification of strong substitutions
We identified strong amino acid substitutions (hereafter, "strong substitutions") using G-A, G-B, and G-1 to G-3 data. The beneficial substitution rate was calculated based on the frequency that a certain substitution appears in the strong AMPs. To do this, all the data were divided into three subpopulations, strong, medium, and weak peptides according to the IC50 values. The number of peptides which has the same sequence was counted in the individual sub-population. Then the beneficial substitution rate was calculated using the equation below:
The number of peptides with the same sequence was counted and the beneficial substitution rate was calculated with these numbers. The top 20 beneficial substitutions (Table S3 ). Their beneficial rates were more than 50%. A set of 40 unique peptides was generated by randomly introducing these possible strong substitutions. Note that the new peptides were not generated in the previous generations.
Peptide synthesis
All peptides were synthesized on a SyroII parallel peptide synthesizer equipped with 96 × 2 mL, 25 µmol reactors (MultiSynTech GmbH, Germany). All Fmoc-protected amino acids and resins were purchased from Activotec Ltd, UK. HOBt, HBTU, DMF, NMP, DIPEA and DCM were purchased from AGTC Bioporducts Ltd, UK. DIC, TFA and diethyl ether were purchased from Sigma-Aldrich, Fisher Scientific and Alfa Aesar, respectively.
Cleavage of the resin was achieved by using a cleavage cocktail comprising 94 mL TFA, 4 mL triisopropylsilane and 2 mL H2O. 1 mL of cleavage cocktail was dispensed into each reactor and the reactor blocks were vortexed on a shaker for 3 hours. Filtration was achieved using a transfer station (MultiSynTech GmbH, Germany) which uses N2 pressure to transfer the peptide and cleave cocktail mixture into a 15 mL centrifuge tube (Sarstedt, Germany). Peptides were precipitated by addition of cold diethyl ether (10 mL). The precipitated peptides were centrifuged and washed 4 more times with diethyl ether. The peptides were dried in a vacuum desiccator overnight before HPLC analysis, mass spectroscopy (See Figure S7 -S8) and antimicrobial assay.
HPLC analysis
Percentage peptide purity was assessed on a Dionex 3000 Ulitmate HPLC system comprising LPG-3400SD pump, DAD-3000 detector with a 13 µL flow cell, WPS-3000TFC analytical autosampler with fraction collector, and TCC-3000SD column thermostat, running Chromeleon 6.8. A C18, 300 Å, 2.1mm I.D. column × 150 mm column was used. The method was as follows, 5% B for 5 mins, increasing to 60% B over 15 mins, staying at 60% B for 5 mins before returning to initial conditions over 2.5 mins. Buffer A: 95% H2O, 5% MeCN, 0.1% TFA. Buffer B: 95% MeCN, 5% H2O, 0.1% TFA. The peptides with purity higher than 70 % were used for the in vitro bacterial assay. The average purity of all the peptides used for the bacterial assay was 87.22 ± 7.21 % (mean±s. d.).
In vitro bacterial assay
The antimicrobial activity of synthesized peptides was measured using a modified broth microdilution method. 4 Escherichia coli strain MG1655 was purchased from DSMZ (Germany) and used throughout this study. Bacterial cells were grown in 30 ml flat-bottomed glass vials (VWR,548-0155) in a shaking incubator (Grant Instruments, ES-20) for 18 h at 30 ˚C prior to assay experiments. Muller Hinton II broth (MHB) was used as culture medium for all the experiments. The synthesized peptides above the purity criteria were used for the assay: 80, 60, 59, 53, 27, 83, 84, and 87 new sequences were tested for generation A, B, 1, 2 and 3, and control generation 1, 2, and 3, respectively. The peptide solutions were prepared from powder stocks just prior to the experiments to avoid peptide degradation. The solvents were water, DMF or Acetic Acid to prepare stock solutions, depending on the solubility calculated from the hydrophobicity and charge of the peptide sequence. The stock solutions were generally prepared at 100-fold high concentration than a final concentration for the assay. Therefore, the amount of solvents carried over to cell culture solutions for in vitro assay were very small and had little effect on determining IC50 values.
The assay was performed in sterile 96-well, flat bottom polypropylene microtiter plates. The first column had the clinically used antibiotic, ampicillin for the control experiment. From the second to the 11th column, each had different peptides. The first row had the highest peptide concentration and the bottom row was without peptides. Antibiotic/peptide concentrations across the rows were diluted by a factor of 2. Then the bacterial culture was added to a final volume of 200 μl. The last column had no antibiotics or peptides, and every other well were inoculated with E. coli to get a blank and positive control for the bacterial culture. The inoculum size was 5 X 10 5 colony-forming units (cfu) / ml. Cells in 96-well plates were grown for 18 hours in an incubator at 37°C with rapid shaking at 1000 rpm. Optical densities of the cells at 600 nm (OD600) were measured after the incubation using a plate reader (Infinite M200, Tecan). The OD600 values of bacterial culture were plotted against the peptide concentrations, and the peptide antimicrobial activity was evaluated as
